The system is available for patients whose mitral valves are not working properly due to severe mitral annular calcification.

Abbott announced the FDA approved its transcatheter mitral valve replacement system for patients with severe mitral annular ...

Abbott said the Tendyne system addresses a significant unmet need in cardiac care, providing an option for patients ineligible for open heart surgery and whose valves cannot be successfully repaired ...

The FDA approved Abbott's Tendyne minimally invasive heart replacement for mitral valve disease that could disqualify ...

Abbott (NYSE: ABT) announced today that it received FDA approval for its Tendyne transcatheter mitral valve replacement (TMVR ...

The FDA gave the OK for the North Chicago-based medical device maker's Tendyne transcatheter mitral valve replacement.

For patients with severe MAC who are at high risk for open-heart surgery and whose mitral valve cannot be successfully repaired with the Abbott MitraClip™ device, Tendyne offers an alternative ...

Abbott today announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendynetm transcatheter mitral valve replacement (TMVR) system to treat people with mitral valve disease.

ABT wins FDA approval for its Tendyne TMVR system, offering a minimally invasive mitral valve replacement for high-risk patients with severe MAC.

The Tendyne system is designated for those who are at high risk for traditional open-heart surgery. It helps with those with ...

Boston Scientific is pulling its latest transcatheter aortic heart valve platform from the worldwide market and said it will ...